Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25594317 | 0.70 | — | — | |
| SCHEMBL9972650 | 0.70 | — | — | |
| SCHEMBL13144672 | 0.70 | — | — | |
| SCHEMBL9186443 | 0.67 | — | — | |
| SCHEMBL12434845 | 0.67 | — | — | |
| SCHEMBL15928062 | 0.65 | HIF1A (0.39) | — | |
| SCHEMBL16305039 | 0.64 | ALPL (0.31) | ALPL | |
| SCHEMBL2267693 | 0.62 | — | — | |
| SCHEMBL3990277 | 0.62 | HIF1A (0.36) | — | |
| SCHEMBL23096881 | 0.62 | ALPL (0.32) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544151-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190023710-A1 | NOVEL COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023710-A1 | NOVEL COMPOUNDS AND USES THEREOF | RB1, VEGFA, UACA | ALPL 4532/4885 |
| US-10544151-B2 | Compounds and uses thereof | RB1, VEGFA, KDR | ALPL 4450/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | ALPL 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.